Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC maintenance therapy in moderately to severely active ulcerative colitis
2019-003849-15Phase 3Completed
- Sponsor
- Celltrion
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing CT-P13 SC maintenance with Placebo SC (2 arms). Primary endpoint: Clinical remission at Week 54. Started Feb 2020; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003849-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003849-15.